查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197119

醫療保健納米技術（納米醫學）市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，醫療保健納米技術（納米醫學）市場預計將以 11.9% 左右的複合年增長率增長。

納米技術的使用為開發預防、診斷和治療 COVID-19 和其他病毒感染的新策略提供了新的機會。 隨著納米材料的開發，如消毒劑、個人防護設備、診斷系統和用於治療和疫苗開發的納米載體系統，COVID-19 管理得以實現。 根據 Estefania V. R. Campos 等人於 2020 年發表在 Journal of Nanobiotechnology 上的研究論文，硫醇修飾的探針在金納米粒子表面功能化並與靶標雜交，以防止納米粒子因鹽而聚集。結果，它可以防止顏色變化。 該解決方案可輕鬆適用於 COVID-19 的診斷。

醫療保健納米技術（納米醫學）市場受多種因素驅動。

納米醫學可以幫助改善人類健康，並為多種危及生命的疾病提供解決方案，包括癌症、帕金森氏症、阿爾茨海默氏症、糖尿病、骨科疾病以及與血液、肺和循環系統相關的疾病。它提供 據國際阿爾茨海默氏症協會稱，到 2020 年，全球將有大約 5000 萬癡呆症患者。 這個數字預計每 20 年翻一番，到 2030 年達到 8200 萬，到 2050 年達到 1.52 億。 因此，預計癡呆症的高負擔將推動在疾病管理中對基於納米藥物的有效療法的需求，從而推動市場增長。

此外，市場參與者正在努力頻繁發布產品以增加他們的影響力。 例如，2020 年 10 月，Medtronic PLC 推出了新的 Adaptix Interbody System，這是一種採用 Titan nanoLOCK 表面技術的導航鈦脊柱植入物。

然而，與傳統藥物相比，納米顆粒輔助藥物的嚴格監管問題和高成本阻礙了市場增長。

醫療保健納米技術市場趨勢

預計腫瘤疾病領域在預測期內將呈現更好的增長

納米醫學是一種很有前途的癌症治療模式。 可以利用這一不斷發展的醫學研究領域來發現針對包括癌症在內的多種疾病的更加個性化的治療方法。 在全球範圍內，癌症的患病率正在增加。 例如，根據GLOBOCAN，2020，預計2020年全球癌症患者人數將增加到1930萬，癌症死亡人數將增加到1000萬。

在腫瘤學領域，納米醫學為現有的癌症治療和診斷方法帶來了充滿希望的變革。 基於納米的癌症治療和診斷的採用取得了顯著進展，目前正在進行一些新的發展。

根據 2021 年 7 月發表的研究論文“用於納米醫學和癌症的納米材料開發的最新進展”，具有不同形狀、尺寸和成分的各種工程納米材料可用於各種生物醫學應用。已開發出一個納米平台. 納米材料和設備也被廣泛用於開發即時和高靈敏度的癌症檢測方法。 因此，用於癌症檢測的納米醫學的進步正在推動市場增長。

此外，使用納米醫學技術的抗癌藥物的頻繁上市也在顯著推動市場。 2019 年 4 月，處於臨床階段的納米藥物公司 Nanobiotix 宣布了結晶氧化鉿 (HfO2) 納米顆粒，該納米顆粒設計用於在晚期軟組織肉瘤患者的首次標準放療前直接注射到腫瘤中。其水性懸浮液“Hensify ( NBTXR3)”。

在 Ye Zhang 等人發表於 2019 年血液學與腫瘤學雜誌的研究論文中，紀念斯隆-凱特琳癌症中心和康奈爾大學的研究人員開發了二氧化矽雜化納米顆粒 (Cdots)。 這些與 124 I 標記的環-[Arg-Gly-Asp-Tyr] (cRGDY) □綴合的納米顆粒可以選擇性地結合整合素，因此可以用作腫瘤細胞探針。

預計北美市場份額最大

市場增長主要由與慢性病和急性病的早期診斷、預防性干預和預防相關的技術進步和應用推動，預計這些將推動美國的市場增長。

例如，根據美國疾病控制與預防中心的數據，到 2021 年，心髒病將導緻美國四分之一的死亡。 冠心病是美國心血管疾病死亡的主要原因，有 360,900 人死亡，其次是中風 (805,000 人)。 這種高負擔可能會導致對特定治療性納米載體、納米結構支架和組織再生植入物的高需求。

此外，該國正在進行多項與基於納米技術的藥物和診斷相關的研發活動，這可能是市場增長的推動力。 例如，2020 年 1 月，斯坦福大學的研究人員開發了一種納米顆粒塗層藥物，該藥物通過減少動脈中的斑塊積聚而不會引起有害的副作用，從而限制小鼠動脈粥樣硬化的進展。

此外，一些主要的國內市場參與者正在開發新產品和技術以與現有產品競爭，而另一些則正在開發其他符合市場趨勢的公司。我們正在進行收購和合作。 2020年，Nanox Imaging 和 SPI Medical 達成協議，在墨西哥銷售和引進 Nanox 的新型 X 射線設備。 Nanox ARC 使用納米技術和半導體來取代傳統機器中的陰極射線管。

此外，在 COVID-19 大流行期間，人們發現納米醫學在疫苗開發中發揮著重要作用。 該地區的科學家和市場參與者正在進行越來越多的實驗研究，以找到能夠有效對抗高度傳染性 COVID-19 病毒的合適且有前途的療法。 2020 年 10 月，加拿大政府宣布向 Precision Nanosystems 提供 1820 萬美元的資金，用於開發針對 COVID-19 的 RNA 疫苗。 這項投資將支持使用基於脂質的藥物輸送系統和納米藥物開發具有成本效益的 COVID-19 疫苗。

醫療保健納米技術市場的競爭對手分析

主要市場參與者正在關注藥物生物利用度和藥物管理方面的技術進步和改進。 預計 COVID-19 大流行帶來的有利增長機會將推動新參與者進入市場。 市場上的主要參與者包括 Sanofi SA、輝瑞公司、Celgene 公司、Luminex 公司、台灣脂質體有限公司。 此外，一些公司正在努力將基於納米技術的藥物和診斷工具推向市場。 例如，2020 年 8 月，Promimic 合作夥伴 Innovasis Inc. 獲得美國 FDA 批准推出用於脊柱融合手術的 3D 打印植入物。 此外，這些植入物使用了 Promimic 的 HAnano 表面技術，這是一種在植入裝置表面進行的生物活性納米處理，可增加醫療植入物的分子錨定。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動力
    • 癌症、遺傳病和心血管疾病的患病率增加
    • 診斷程序中納米級技術的進步
    • 對個性化醫療的偏好不斷上升
  • 市場製約因素
    • 成本高
    • 對商業介紹的嚴格監管
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 通過申請
    • 給藥
    • 生物材料
    • 主動植入
    • 影像診斷
    • 組織再生
  • 按疾病分類
    • 心血管疾病
    • 癌症相關疾病
    • 神經系統疾病
    • 骨科
    • 感染
    • 其他疾病
  • 按地區細分
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 法國
      • 德國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • CytImmune Sciences Inc.
    • Johnson & Johnson
    • Luminex Corporation
    • Merck & Co. Inc.
    • Nanobiotix
    • Pfizer Inc.
    • Starpharma Holdings Limited
    • Taiwan Liposome Company Ltd
    • Copernicus Therapeutics Inc.
    • NanoCarrier Co. Ltd
    • Ensysce Biosciences Inc.
    • Ocuphire Pharma Inc.
    • LiPlasome Pharma ApS
    • Nami Therapeutics Corp.
    • Nanospectra Biosciences
    • CytImmune Sciences
    • Genetic Immunity
    • Spago Nanomedical AB

第7章 市場機會與今後動向

簡介目錄
Product Code: 52957

The healthcare nanotechnology (nanomedicine) market is expected to register a CAGR of nearly 11.9% during the forecast period.

The use of nanotechnology offers new opportunities for the development of novel strategies in terms of prevention, diagnosis, and treatment of COVID-19 and other viral infections. COVID-19 management was done with the development of nano-based materials, such as disinfectants, personal protective equipment, diagnostic systems, and nanocarrier systems, for treatments and vaccine development. According to a research article by Estefania V. R. Campos et al., published in the Journal of Nanobiotechnology in 2020, gold nanoparticles were functionalized with probes modified with thiol on the surface, which hybridize with the target and prevent the aggregation of the nanoparticles by salts and, consequently, the color change. This solution can be easily adapted for the diagnosis of COVID-19.

The healthcare nanotechnology (nanomedicine) market is being driven by various factors, such as the growing prevalence of cancer and genetic and cardiovascular diseases, increasing advancements in nanoscale technologies for diagnostic procedures, and growing preference for personalized medicines.

Nanomedicine helps improve human health and offers solutions for various life-threatening diseases, such as cancer, Parkinson's disease, Alzheimer's disease, diabetes, orthopedic diseases, and diseases related to blood, lungs, and the cardiovascular system. According to Alzheimer's Disease International, globally, there were around 50 million people with dementia in 2020. This number is expected to double every 20 years, reaching 82 million in 2030 and 152 million in 2050. Therefore, the high burden of dementia is expected to increase the demand for effective therapeutics based on nanomedicine in the management of the disease, which is expected to drive market growth.

Moreover, the market players are involved in frequent product launches to enhance their presence. For instance, in October 2020, Medtronic PLC launched its new Adaptix Interbody System, a navigated titanium spinal implant with the Titan nanoLOCK Surface Technology.

However, stringent regulatory issues and the high cost of nanoparticle-assisted medicine relative to its traditional counterparts are hindering the market's growth.

Healthcare Nanotechnology Market Trends

The Oncological Diseases Segment is Expected to Show Better Growth During the Forecast Period

Nanomedicine is a promising mode of cancer treatment. This growing field of medical research can be used to discover better-personalized treatments for a wide range of diseases, including cancer. Globally, the prevalence of cancer is increasing. For instance, according to GLOBOCAN, 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020.​

In the field of oncology, nanomedicine offers promising transformations from the existing methods of treatments and diagnosis of cancer. The adoption of nano-based cancer therapies and diagnostics witnessed noteworthy progress, and numerous new developments are currently in the pipeline.

According to a research article titled "Recent Advances in Nanomaterials Development for Nanomedicine and Cancer", published in July 2021, a wide range of engineered nanomaterials and nanoplatforms with different shapes, sizes, and compositions has been developed for various biomedical applications. The nano-based materials and devices have also been used extensively to develop point-of-care and highly sensitive methods of cancer detection. Thus, advances in nanomedicine for the detection of cancer are driving the market's growth.

Moreover, the frequent launches of cancer medicines with nanomedicine technology are driving the market significantly. In April 2019, Nanobiotix, a clinical-stage nanomedicine company, obtained the CE approval for its Hensify (NBTXR3), an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into the tumor before a patient's first standard radiotherapy treatment of advanced soft tissue sarcoma.

According to a research article by Ye Zhang et al., published in the Journal of Hematology & Oncology Journal 2019, researchers at the Memorial Sloan Kettering Cancer Center and Cornell University developed silica-hybrid nanoparticles (C-dots) for PET imaging of patients with metastatic melanoma or malignant brain tumors. These nanoparticles, coupled with 124I-labeled cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, can selectively bind to integrins and can be used to probe tumor cells.

North America is Expected to Hold the Largest Share of the Market

The major factors attributing to the market's growth are technological advancements, coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic and acute disorders, which are expected to bolster the market's growth in the United States.

For instance, according to the Centers for Disease Control and Prevention, 2021, heart disease accounted for one in four deaths in the United States. Coronary heart disease is the leading cause of deaths attributable to cardiovascular disease in the United States, causing 360,900 deaths, followed by stroke (805,000). This high burden may lead to the high demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Moreover, several R&D activities are ongoing in the country on drugs and diagnostics based on nanotechnology, which may drive market growth. For instance, in January 2020, researchers from Stanford University developed a drug coated with nanoparticles that limits the development of atherosclerosis in mice by reducing plaque buildup in their arteries without causing harmful side effects.

Additionally, a few of the key market players in the country are developing novel products and technologies to compete with the existing products, while others are acquiring and partnering with other companies trending in the market. In 2020, Nano-X Imaging and SPI Medical entered an agreement to distribute and introduce Nanox's novel X-ray systems in Mexico. Nanox ARC uses nanotechnology and semiconductors to replace the cathode ray tubes in traditional machines.

Additionally, during the COVID-19 pandemic, nanomedicine has been found to play a key role in the development of vaccines. Scientists and market players in the region are increasing experimental studies to find suitable and promising therapeutics that may effectively tackle the highly contagious COVID-19 virus. In October 2020, the Canadian government announced the funding of USD 18.2 million to Precision NanoSystems to develop an RNA vaccine for COVID-19. This investment will support the development of a cost-effective COVID-19 vaccine by using lipid-based drug delivery systems and nanomedicine.

Healthcare Nanotechnology Market Competitor Analysis

The major market players are focusing on technological advancements and improvements in drug bioavailability and drug administration. Lucrative growth opportunities due to the COVID-19 pandemic are expected to drive the entry of new players into the market. Some of the major players in the market are Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd. Moreover, several companies are working on launching nanotechnology-based medicines and diagnostic tools. For instance, in August 2020, Promimic's partner, Innovasis Inc., received the US FDA clearance to launch 3D-printed implants used in spinal fusion surgery. In addition, these implants use Promimic's HAnano Surface Technology, a bioactive nano treatment for implant device surfaces that leads to increased molecular anchoring of medical implants.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases
    • 4.2.2 Increasing Advancements in Nanoscale Technologies for Diagnostic Procedures
    • 4.2.3 Growing Preference for Personalized Medicines
  • 4.3 Market Restraints
    • 4.3.1 High Costs
    • 4.3.2 Stringent Regulations for Commercial Introduction
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Application
    • 5.1.1 Drug Delivery
    • 5.1.2 Biomaterials
    • 5.1.3 Active Implants
    • 5.1.4 Diagnostic Imaging
    • 5.1.5 Tissue Regeneration
  • 5.2 By Disease
    • 5.2.1 Cardiovascular Diseases
    • 5.2.2 Oncological Diseases
    • 5.2.3 Neurological Diseases
    • 5.2.4 Orthopedic Diseases
    • 5.2.5 Infectious Diseases
    • 5.2.6 Other Diseases
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 France
      • 5.3.2.2 Germany
      • 5.3.2.3 United Kingdom
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sanofi SA
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 CytImmune Sciences Inc.
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Luminex Corporation
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Nanobiotix
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Starpharma Holdings Limited
    • 6.1.10 Taiwan Liposome Company Ltd
    • 6.1.11 Copernicus Therapeutics Inc.
    • 6.1.12 NanoCarrier Co. Ltd
    • 6.1.13 Ensysce Biosciences Inc.
    • 6.1.14 Ocuphire Pharma Inc.
    • 6.1.15 LiPlasome Pharma ApS
    • 6.1.16 Nami Therapeutics Corp.
    • 6.1.17 Nanospectra Biosciences
    • 6.1.18 CytImmune Sciences
    • 6.1.19 Genetic Immunity
    • 6.1.20 Spago Nanomedical AB

7 MARKET OPPORTUNITIES AND FUTURE TRENDS